Retinoblastoma is the most common primary intraocular malignancy in children. The management of retinoblastoma is complex and depends on several factors.
Methods
This review provides an update on current and emerging therapeutic options for retinoblastoma. The medical literature was searched for articles relevant to the management of retinoblastoma. The results of prospective and retrospective studies on chemotherapy and focal therapy for retinoblastoma are summarized. Animal models for novel therapeutic agents are also discussed.
Results
Treatment strategies for retinoblastoma involve intravenous chemoreduction, local administration routes of chemotherapy (eg, intra-arterial, intravitreal), focal therapy for tumor consolidation (eg, photocoagulation, thermotherapy, cryotherapy, plaque brachytherapy), external beam radiotherapy, and surgical enucleation. Emerging therapies include alternative chemotherapeutic agents, molecularly targeted therapies, and novel drug-delivery systems.
Conclusion
In the past 10 years, the management strategy for retinoblastoma has significantly changed, shifting toward local chemotherapy and away from systemic chemotherapy. Innovations in the field of molecular biology and the development of targeted therapies have led to improvements in survival rates and ocular salvage for this disease. However, the need still exists to further assess the long-term effects of such directional changes in therapy.
References
1.
BroaddusE., TophamA., SinghA.D.Incidence of retinoblastoma in the USA: 1975-2004.Br J Ophthalmol.2009; 93(1): 21–23.
2.
ParkinD.M., StillerC.A., DraperG.J.The international incidence of childhood cancer.Int J Cancer.1988; 42(4): 511–520.
3.
TamboliD., TophamA., SinghN.Retinoblastoma: a SEER dataset evaluation for treatment patterns, survival, and second malignant neoplasms.Am J Ophthalmol.2015; 160(5): 953–958.
4.
BroaddusE., TophamA., SinghA.D.Survival with retinoblastoma in the USA: 1975-2004.Br J Ophthalmol.2009; 93(1): 24–27.
5.
GrossniklausH.E.Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.Am J Ophthalmol.2014; 158(5): 875–891.
6.
CanturkS., QaddoumiI., KhetanV. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators.Br J Ophthalmol.2010; 94(11): 1432–1436.
7.
AbramsonD.H., ShieldsC.L., MunierF.L.Treatment of retinoblastoma in 2015: agreement and disagreement.JAMA Ophthalmol.2015; 133(11): 1341–1347.
PritchardE.M., DyerM.A., GuyR.K.Progress in small molecule therapeutics for the treatment of retinoblastoma.Mini Rev Med Chem.2016; 16(6): 430–454.
10.
Chévez-BarriosP., HurwitzM.Y., LouieK. Metastatic and non-metastatic models of retinoblastoma.Am J Pathol.2000; 157(4): 1405–1412.
11.
ShieldsC.L., LallyS.E., LeaheyA.M.Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy.Curr Opin Ophthalmol.2014; 25(5): 374–385.
12.
ShieldsC.L., ShieldsJ.A.Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy.Curr Opin Ophthalmol.2010; 21(3): 203–212.
13.
Linn MurphreeA.Intraocular retinoblastoma: the case for a new group classification.Ophthalmol Clin North Am.2005; 18(1): 41–53.
14.
ShieldsC.L., MashayekhiA., AuA.K.The International classification of retinoblastoma predicts chemoreduction success.Ophthalmology.2006; 113(12): 2276–2280.
KalikiS., ShieldsC.L., RojanapornD.High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes.Ophthalmology.2013; 120(5): 997–1003.
17.
RamasubramanianA., KytastyC., MeadowsA.T.Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era.Am J Ophthalmol.2013; 156(4): 825–829.
18.
Rodriguez-GalindoC., ChantadaG.L., HaikB.G.Treatment of retinoblastoma: current status and future perspectives.Curr Treat Options Neurol.2007; 9(4): 294–307.
19.
KingstonJ.E., HungerfordJ.L., MadreperlaS.A.Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma.Arch Ophthalmol.1996; 114(11): 1339–1343.
20.
ShieldsC.L., HonavarS.G., MeadowsA.T.Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.Am J Ophthalmol.2002; 133(5): 657–664.
21.
SullivanE.M., WilsonM.W., BillupsC.A.Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.J Pediatr Hematol Oncol.2014; 36(6): e335–340.
22.
ChantadaG.L., DunkelI.J., de DavilaM.T.Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy?Br J Ophthalmol.2004; 88(8): 1069–1073.
23.
ShortB.G.Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.Toxicol Pathol.2008; 36(1): 49–62.
DemirciH., EagleR.C.Jr, ShieldsC.L.Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.Arch Ophthalmol.2003; 121(8): 1125–1131.
26.
InomataM., KanekoA.Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay.Jpn J Cancer Res.1987; 78(8): 858–868.
27.
YamaneT., KanekoA., MohriM.The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma.Int J Clin Oncol.2004; 9(2): 69–73.
28.
SuzukiS., YamaneT., MohriM.Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis.Ophthalmology.2011; 118(10): 2081–2087.
29.
AbramsonD.H., DunkelI.J., BrodieS.E.A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.Ophthalmology.2008; 115(8): 1398–1404.
30.
ShieldsC.L., ManjandavidaF.P., LallyS.E.Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma.Ophthalmology.2014; 121(7): 1453–1460.
31.
AbramsonD.H., DanielsA.B., MarrB.P.Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma.PLoS One.2016; 11(1): e0146582.
32.
ShieldsC.L., KalikiS., ShahS.U.Effect of intraarterial chemotherapy on retinoblastoma-induced retinal detachment.Retina.2012; 32(4): 799–804.
33.
PaliouraS., GobinY.P., BrodieS.E.Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment.Pediatr Blood Cancer.2012; 59(5): 859–864.
34.
GobinY.P., DunkelI.J., MarrB.P.Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma.PLoS One.2012; 7(9): e44322.
35.
TseB.C., SteinleJ.J., JohnsonD.Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings.JAMA Ophthalmol.2013; 131(7): 903–911.
36.
SteinleJ.J., ZhangQ., ThompsonK.E.Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.Invest Ophthalmol Vis Sci.2012; 53(4): 2439–2445.
37.
VajzovicL.M., MurrayT.G., Aziz-SultanM.A.Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma.Clin Ophthalmol.2011; 5: 171–176.
38.
JabbourP., ChalouhiN., TjoumakarisS.Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma.J Neurosurg Pediatr.2012; 10(3): 175–181.
39.
AzizH.A., LasennaC.E., VigodaM.Retinoblastoma treatment burden and economic cost: impact of age at diagnosis and selection of primary therapy.Clin Ophthalmol.2012; 6: 1601–1606.
40.
ZanatyM., BarrosG., ChalouhiN.Update on intra-arterial chemotherapy for retinoblastoma.Sci World J.2014; 2014: 869604.
41.
ZhaoJ., DimarasH., MasseyC.Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis.J Clin Oncol.2011; 29(7): 845–851.
42.
MunierF.L., SolimanS., MoulinA.P.Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.Br J Ophthalmol.2012; 96(8): 1084–1087.
43.
GhassemiF., ShieldsC.L., GhadimiH.Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.JAMA Ophthalmol.2014; 132(8): 936–941.
44.
GhassemiF., ShieldsC.L.Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.Arch Ophthalmol.2012; 130(10): 1268–1271.
45.
KanekoA., SuzukiS.Eye-preservation treatment of retinoblastoma with vitreous seeding.Jpn J Clin Oncol.2003; 33(12): 601–607.
46.
SmithS.J., SmithB.D.Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review.Br J Ophthalmol.2013; 97(10): 1231–1236.
47.
MunierF.L., GaillardM.C., BalmerA.Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives.Saudi J Ophthalmol.2013; 27(3): 147–150.
48.
SeregardS., SinghA.D.Retinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavity.Br J Ophthalmol.2012; 96(4): 473–474.
49.
SuzukiS., AiharaY., FujiwaraM.Intravitreal injection of melphalan for intraocular retinoblastoma.Jpn J Ophthalmol.2015; 59(3): 164–172.
50.
FrancisJ.H., SchaiquevichP., BuitragoE.Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.Ophthalmology.2014; 121(9): 1810–1817.
51.
GeroskiD.H., EdelhauserH.F.Transscleral drug delivery for posterior segment disease.Adv Drug Deliv Rev.2001; 52(1): 37–48.
52.
HaydenB.C., JockovichM.E., MurrayT.G.Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma.Invest Ophthalmol Vis Sci.2004; 45(10): 3644–3649.
53.
AbramsonD.H., FrankC.M., DunkelI.J.A phase I/II study of sub-conjunctival carboplatin for intraocular retinoblastoma.Ophthalmology.1999; 106(10): 1947–1950.
54.
MulvihillA., BudningA., JayV.Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.Arch Ophthalmol.2003; 121(8): 1120–1124.
55.
SchmackI., HubbardG.B., KangS.J.Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma.Am J Ophthalmol.2006; 142(2): 310–315.
56.
ShieldsC.L., MashayekhiA., CaterJ.Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.Arch Ophthalmol.2005; 123(6): 765–773.
57.
SchiedlerV., DubovyS.R., MurrayT.G.Snare technique for enucleation of eyes with advanced retinoblastoma.Arch Ophthalmol.2007; 125(5): 680–683.
58.
SastreX., ChantadaG.L., DozF.Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma.Arch Pathol Lab Med.2009; 133(8): 1199–1202.
ImhofS.M., MouritsM.P., HofmanP.Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma.Ophthalmology.1996; 103(2): 263–268.
61.
WongF.L., BoiceJ.D.Jr, AbramsonD.H.Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.JAMA.1997; 278(15): 1262–1267.
62.
MareesT., MollA.C., ImhofS.M.Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.J Natl Cancer Inst.2008; 100(24): 1771–1779.
63.
WongJ.R., MortonL.M., TuckerM.A.Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.J Clin Oncol.2014; 32(29): 3284–3290.
64.
AliM.J., HonavarS.G., ReddyV.A.Orbital retinoblastoma: present status and future challenges - a review.Saudi J Ophthalmol.2011; 25(2): 159–167.
65.
TruongB., GreenA.L., FriedrichP.Ethnic, racial, and socioeconomic disparities in retinoblastoma.JAMA Pediatr.2015; 169(12): 1096–1104.
66.
RadhakrishnanV., KashyapS., PushkerN.Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study.Ophthalmology.2012; 119(7): 1470–1477.
67.
DunkelI.J., ChanH.S., JubranR.High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.Pediatr Blood Cancer.2010; 55(1): 149–152.
TsuiJ.Y., DalgardC., Van QuillK.R.Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.Invest Ophthalmol Vis Sci.2008; 49(2): 490–496.
70.
MallipatnaA.C., DimarasH., ChanH.S.Periocular topotecan for intraocular retinoblastoma.Arch Ophthalmol.2011; 129(6): 738–745.
71.
ChantadaG.L., FandinoA.C., CasakS.J.Activity of topotecan in retinoblastoma.Ophthalmic Genet.2004; 25(1): 37–43.
BuitragoE., Del SoleM.J., TorbidoniA.Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.Exp Eye Res.2013; 108: 103–109.
74.
BuitragoE., HochtC., ChantadaG.Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.Exp Eye Res.2010; 91(1): 9–14.
75.
JijelavaK., KompellaU., DurazoS.Evaluation of the efficacy of topotecan Au-tethered liposomes and AU-011 for the treatment of retinoblastoma in vitro.Invest Ophthamol Visual Sci.2014. http://iovs.arvojournals.org/article.aspx?articleid=2268458. Accessed March 29, 2016.
76.
ChantadaG.L., FandinoA., MatoG.Phase II window of idarubicin in children with extraocular retinoblastoma.J Clin Oncol.1999; 17(6): 1847–1850.
77.
HuT., LeQ., WuZ.Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-beta-hydroxybutyrate microspheres.J Pharm Biomed Anal.2007; 43(1): 263–269.
78.
FriendS.H., BernardsR., RogeljS.A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.Nature.1986; 323(6089): 643–646.
79.
CorsonT.W., GallieB.L.One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma.Genes Chromosomes Cancer.2007; 46(7): 617–634.
80.
KapataiG., BrundlerM.A., JenkinsonH.Gene expression profiling identifies different sub-types of retinoblastoma.Br J Cancer.2013; 109(2): 512–525.
81.
SachdevaU.M., O'BrienJ.M.Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.J Clin Invest.2012; 122(2): 425–434.
82.
LaurieN.A., DonovanS.L., ShihC.S.Inactivation of the p53 pathway in retinoblastoma.Nature.2006; 444(7115): 61–66.
83.
BrennanR.C., FedericoS., BradleyC.Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.Cancer Res.2011; 71(12): 4205–4213.
84.
ZhangJ., BenaventeC.A., McEvoyJ.A novel retinoblastoma therapy from genomic and epigenetic analyses.Nature.2012; 481(7381): 329–334.
85.
GobessiS., LaurentiL., LongoP.G.Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.Leukemia.2009; 23(4): 686–697.
86.
AzmiA.S., WangZ., PhilipP.A.Emerging Bcl-2 inhibitors for the treatment of cancer.Expert Opin Emerg Drugs.2011; 16(1): 59–70.
87.
FalkenbergK.J., JohnstoneR.W.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Nat Rev Drug Discov.2014; 13(9): 673–691.
88.
ZhaoY., TanJ., ZhuangL.Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.Proc Natl Acad Sci U S A.2005; 102(44): 16090–10695.
89.
DalgardC.L., Van QuillK.R., O'BrienJ.M.Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.Clin Cancer Res.2008; 14(10): 3113–3123.
90.
Chevez-BarriosP., ChintagumpalaM., MielerW.Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir.J Clin Oncol.2005; 23(31): 7927–7935.
91.
BertrandN., WuJ., XuX.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Adv Drug Deliv Rev.2014; 66: 2–25.
92.
SalmasoS., CalicetiP.Stealth properties to improve therapeutic efficacy of drug nanocarriers.J Drug Deliv.2013; 2013: 374252.
93.
BhavsarD., SubramanianK., SethuramanS.Management of retinoblastoma: opportunities and challenges.Drug Deliv.2015: 1–9.
94.
KangS.J., DurairajC., KompellaU.B.Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.Arch Ophthalmol.2009; 127(8): 1043–1047.
95.
BodduS.H., JwalaJ., ChowdhuryM.R.In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using doxorubicin as a model drug.J Ocul Pharmacol Ther.2010; 26(5): 459–468.
96.
MitraM., DilnawazF., MisraR.Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy.Cancer Nanotechnol.2011; 2(1-6): 21–36.
97.
ChoiW.I., SahuA., KimY.H.Photothermal cancer therapy and imaging based on gold nanorods.Ann Biomed Eng.2012; 40(2): 534–546.
98.
MenonJ.U., JadejaP., TambeP.Nanomaterials for photo-based diagnostic and therapeutic applications.Theranostics.2013; 3(3): 152–166.
99.
YavuzM.S., ChengY., ChenJ.Gold nanocages covered by smart polymers for controlled release with near-infrared light.Nat Mater.2009; 8(12): 935–939.
100.
KimJ.H., KimJ.H., KimK.W.Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity.Nanotechnology.2009; 20(50): 505101.
101.
KangS.J., GrossniklausH.E.Rabbit model of retinoblastoma.J Biomed Biotechnol.2011; 2011: 394730.
102.
MartinN.E., KimJ.W., AbramsonD.H.Fibrin sealant for retinoblastoma: where are we?J Ocul Pharmacol Ther.2008; 24(5): 433–438.
103.
GorodetskyR., Peylan-RamuN., ReshefA.Interactions of carboplatin with fibrin(ogen), implications for local slow release chemotherapy.J Control Release.2005; 102(1): 235–245.
104.
Van QuillK.R., DioguardiP.K., TongC.T.Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.Ophthalmology.2005; 112(6): 1151–1158.
105.
SimpsonA.E., GilbertJ.A., RudnickD.E.Transscleral diffusion of carboplatin: an in vitro and in vivo study.Arch Ophthalmol.2002; 120(8): 1069–1074.
106.
YousefY.A., HallidayW., ChanH.S.No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma.Can J Ophthalmol.2013; 48(6): 524–528.
107.
PatelS.R., BerezovskyD.E., McCareyB.E.Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye.Invest Ophthalmol Vis Sci.2012; 53(8): 4433–4441.
108.
KimY.C., OhK.H., EdelhauserH.F.Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles.Eur J Pharm Biopharm.2015; 95(part B): 398–406.
